Press Releases

06.24.2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

06.23.2015

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

06.23.2015

Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts

06.23.2015

New Online Community, Quitter’s Circle, Helps Smokers Trade Cigarettes for Real-Time Support

06.22.2015

Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline

06.11.2015

Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder

06.10.2015

Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)

06.08.2015

Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology

06.04.2015

Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging Through New Campaign

05.30.2015

Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

05.29.2015

Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

05.28.2015

Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer